MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Simulations Plus Inc

Cerrado

SectorSanidad

13.12 1.47

Resumen

Variación precio

24h

Actual

Mínimo

12.56

Máximo

14.93

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+80.91% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.36%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-117M

251M

Apertura anterior

11.65

Cierre anterior

13.12

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

150 / 348 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 abr 2026, 17:04 UTC

Principales Movimientos del Mercado

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 abr 2026, 00:00 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Big Yachts, Big Bucks -- Barrons.com

10 abr 2026, 21:55 UTC

Adquisiciones, fusiones, absorciones

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 abr 2026, 21:01 UTC

Ganancias

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 abr 2026, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

10 abr 2026, 20:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

10 abr 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

10 abr 2026, 20:31 UTC

Charlas de Mercado

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 abr 2026, 20:10 UTC

Adquisiciones, fusiones, absorciones

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 abr 2026, 19:15 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

10 abr 2026, 19:15 UTC

Charlas de Mercado

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 abr 2026, 19:08 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 abr 2026, 19:08 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 abr 2026, 18:38 UTC

Charlas de Mercado

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 abr 2026, 18:25 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Precious Metals Finish With Weekly Gains -- Market Talk

10 abr 2026, 18:05 UTC

Charlas de Mercado

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 abr 2026, 17:31 UTC

Charlas de Mercado
Noticias de Eventos Importantes

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 abr 2026, 17:26 UTC

Ganancias

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 abr 2026, 17:10 UTC

Charlas de Mercado

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 abr 2026, 17:00 UTC

Noticias de Eventos Importantes

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 abr 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

10 abr 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

10 abr 2026, 16:12 UTC

Ganancias

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 abr 2026, 16:11 UTC

Ganancias

Partners Group: Traditional Programs Contributed $3.3B

10 abr 2026, 16:10 UTC

Ganancias

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 abr 2026, 16:10 UTC

Ganancias

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 abr 2026, 16:10 UTC

Ganancias

Partners Group 1Q New Client Demand $8.3B

10 abr 2026, 16:09 UTC

Ganancias

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10 abr 2026, 15:54 UTC

Adquisiciones, fusiones, absorciones

Plenitude Completes Acquisition of Acea Energia

10 abr 2026, 15:38 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

80.91% repunte

Estimación a 12 Meses

Media 23.5 USD  80.91%

Máximo 31 USD

Mínimo 16 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

150 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat